Stay updated with breaking news from Emerging Science Session. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...
Share this article Share this article PALM BEACH, Fla., May 4, 2021 /PRNewswire/ -- Cognitive assessment and training solutions and programs have been witnessing increasing demand due to rise in literacy rates and improved economic conditions among a growing population, especially in developing economies. These programs and tests help students and other users to determine their psychological functions and pace at which information can be processed by the brain. Tests are carried out to determine a person's ability to learn by identifying their strengths and weaknesses, and then, appropriate ...
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Common B-cell depleting therapies, such as rituximab and Ocrevus (ocrelizumab), may result in shorter duration B-cell depleting effects in African American patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) than in white patients, a study suggests. “While previous research has shown that this type of [into-the-vein] therapy is effective for people with those diseases, we also know that Black people tend to ha...
Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021 Slowing of neuropathy progression for all 7 evaluable patients, evidenced by a +1.29 point mean change in NIS, was more favorable than expected progression of +9.2 points Improvement in neuropathy for 3 of these 7 evaluable patients demonstrated by a mean change in NIS of -3.33 points Improvement in cardiac function for all 7 evaluable patients demonstrated by a decrease in global longitudinal strain (GLS) Emerging Science Oral Presentation today at AAN 2021 DUBLIN, Ireland, April 18, 2021 (GLOBE NEWSWIRE)...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation ... Prothena Corporation plcApril 15, 2021 GMT DUBLIN, Ireland, April 15, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that results from its Phase 1 study of PRX004 in ATTR amyloidosis have been ...